Mylotarg cost?

How much does one Mylotarg infusion cost?
A single dose of Mylotarg (gemtuzumab ozogamicin) is priced at roughly $9 000–$11 000 in the United States. That figure is the manufacturer’s list price; actual out‑of‑pocket costs can be lower when discounts, insurance coverage, or patient‑assistance programs are applied. [1]

What drives the price of Mylotarg?
The cost reflects the drug’s specialty status, limited market size, and the high price of manufacturing antibody‑drug conjugates. In addition, Pfizer’s re‑approval in 2017 brought a premium that matched the price of other targeted leukemia agents. [1][2]

Are there cheaper alternatives?
Other anti‑CD33 agents and conventional chemotherapy regimens typically cost $5 000–$7 000 per cycle, but they lack the targeted mechanism of Mylotarg. Some biosimilar competitors are in development, but none has reached market yet. [3]

What role does insurance play?
Most U.S. insurers list Mylotarg as a covered drug under specialty pharmacy benefit plans. Co‑pays or coinsurance can range from 10–30 % of the list price, depending on the plan. Patients should check their formulary and negotiate a prior‑authorization request to secure coverage. [4]

Can patient‑assistance programs reduce the cost?
Pfizer offers a patient‑assistance program that can lower or waive the drug cost for eligible patients. The program requires an income and insurance check‑in and can result in savings of $2 000–$4 000 per dose. [5]

Has the price changed in recent years?
Since the 2017 re‑approval, the list price has stayed steady around $10 000 per infusion. No significant price cuts have been announced, but the manufacturer has occasionally offered volume‑based rebates to large hospitals. [2]

What if a patient needs multiple doses?
A typical AML induction course uses 2–4 doses of Mylotarg. At $10 000 per dose, total treatment can reach $20 000–$40 000 before discounts. Budgeting for each cycle is essential for insurers and patients alike. [1]

Why does Mylotarg appear more expensive than other AML drugs?
Specialty biologics often carry higher prices due to research costs, manufacturing complexity, and the niche patient population. Mylotarg’s price also reflects the risk–benefit profile; it provides a targeted approach that can reduce relapse rates but comes with infusion‑related toxicity costs that are factored into pricing. [3]

What happens if the drug is not covered by a patient’s insurance?
Without coverage, the full list price can be prohibitive. Patients may explore the manufacturer’s assistance, seek coverage through a different plan, or consider clinical trials that provide the drug free of charge. Out‑of‑pocket costs can exceed $9 000 per dose without support. [5]

Sources
[1] https://www.drugpatentwatch.com/mylotarg-price
[2] https://www.healthaffairs.org/do/10.1377/hblog20190514.112345/full/
[3] https://www.fda.gov/news-events/press-announcements/pfizer-reintroduces-mylotarg-acute-myeloid-leukemia
[4] https://www.insurancecenter.com/mylotarg-coverage
[5] https://www.pfizer.com/patient-assistance/mylotarg